Ananda Pharma, one of the UK’s leading clinical-stage pharmaceutical cannabis companies, has announced a string of strategic pivots, including stepping
Amid rising global scrutiny of the wider medical cannabis prescription model, and with markets like France leaning into pharmaceutical-grade regulation, the pharma cannabis sector is shaping up to be one of the most dynamic and closely watched corners of the industry.
In response to this growing exodus of promising biotech firms, the European Union has proposed a new Biotech Act, as part of ongoing efforts by the European Commission to strengthen the continent’s biotechnology and biomanufacturing sectors, which have struggled with fragmented rules and sluggish approval processes.
Ananda Pharma [stock_market_widget type=”chart” template=”line” assets=”ANANF” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Just days after
Ananda Pharma, now the leading force in pharmaceutical cannabis research in the UK, has announced that the former Chief Operating
UK-based cannabinoid pharmaceutical company Ananda Pharma has received ethics approval for a Phase 1 clinical study for its lead compound in Australia.
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
We won’t spam you
